Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000926
Abstract: Background and aims Functioning and symptomatic disease resistant to conventional therapies constitutes a subset amongst neuroendocrine tumors (NETs) that are commonly considered for peptide receptor radionuclide therapy (PRRT). The aim of this study was to… read more here.
Keywords: progressive symptomatic; prrt; neuroendocrine tumors; receptor radionuclide ... See more keywords